Advanced Adc Histogram, Perfusion, And Permeability Metrics Show An Association With Survival And Pseudoprogression In Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report From The Pediatric Brain Tumor Consortium

BACKGROUND AND PURPOSE:Diffuse intrinsic pontine glioma is a lethal childhood brain cancer with dismal prognosis and MR imaging is the primary methodology used for diagnosis and monitoring. Our aim was to determine whether advanced diffusion, perfusion, and permeability MR imaging metrics predict survival and pseudoprogression in children with newly diagnosed diffuse intrinsic pontine glioma.MATERIALS AND METHODS:A clinical trial using the poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor veliparib concurrently with radiation therapy, followed by maintenance therapy with veliparib + temozolomide, in children with diffuse intrinsic pontine glioma was conducted by the Pediatric Brain Tumor Consortium. Standard MR imaging, DWI, dynamic contrast-enhanced perfusion, and DSC perfusion were performed at baseline and approximately every 2 months throughout treatment. ADC histogram metrics of T2-weighted FLAIR and enhancing tumor volume, dynamic contrast-enhanced permeability metrics for enhancing tumors, and tumor relative CBV from DSC perfusion MR imaging were calculated. Baseline values, post-radiation therapy changes, and longitudinal trends for all metrics were evaluated for associations with survival and pseudoprogression.RESULTS:Fifty children were evaluable for survival analyses. Higher baseline relative CBV was associated with shorter progression-free survival (P?=?.02, Q?=?0.089) and overall survival (P?=?.006, Q?=?0.055). Associations of higher baseline mean transfer constant from the blood plasma into the extravascular extracellular space with shorter progression-free survival (P?=?.03, Q?=?0.105) and overall survival (P?=?.03, Q?=?0.102) trended toward significance. An increase in relative CBV with time was associated with shorter progression-free survival (P?更多